Old Web
English
Sign In
Acemap
>
authorDetail
>
Qing Xu
Qing Xu
Food and Drug Administration
Hazard ratio
Boxed warning
Gastroenterology
Refractory
Myeloid leukemia
2
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
FDA Approval Summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
2021
Clinical Cancer Research
E. Dianne Pulte
Kelly J. Norsworthy
Yaping Wang
Qing Xu
Hisham Qosa
Ramadevi Gudi
Donna Przepiorka
Wentao Fu
Olanrewaju O. Okusanya
Kirsten B. Goldberg
R. Angelo de Claro
Ann T. Farrell
Richard Pazdur
Show All
Source
Cite
Save
Citations (3)
Using marginal structural models to analyze the impact of subsequent therapy on the treatment effect in survival data: Simulations and clinical trial examples.
2021
Pharmaceutical Statistics
Qing Xu
Donna Przepiorka
Show All
Source
Cite
Save
Citations (0)
1